Overview
- The declaration, approved at a September 25 plenary and reported publicly in November, states the academy does not endorse puberty blockers, cross-sex hormones or surgeries for anyone under 18.
- The statement argues the interventions pose physical risks that can be irreversible and psychological risks including a high rate of subsequent depression.
- It recommends an integrated, family-centered approach with close mental health support for youths with gender dysphoria, asserting that halting a child’s development is not advisable.
- The academy notes policy reversals or suspensions of pediatric transition treatments in Finland, Sweden, Norway, England, the Netherlands and several U.S. states.
- The pronouncement follows judicial consultations to the academy about procedures such as pharmacological or surgical castration and reassignment, and it aligns with February 2025 changes that restricted such medical interventions to adults under Law 26.743.